论文部分内容阅读
目的:评价新药甲磺酸加替沙星氯化钠注射液治疗常规致病菌引起的呼吸、泌尿系统细菌感染性疾病的疗效和安全性。方法:以加替沙星注射液为对照药,用随机双盲对照实验研究。结果:甲磺酸加替沙星氯化钠注射液组治疗呼吸道和泌尿系统感染的临床总有效率达92.5%,与对照组(87.5%)相比有显著性差异。不良反应发生率为7.5%,与对照组(12.5%)比较差异无统计学意义。结论:甲磺酸加替沙星氯化钠注射液治疗临床常见的致病菌引起的呼吸和泌尿系统感染临床疗效较好,药物不良反应发生率较低。
Objective: To evaluate the efficacy and safety of the new drug gatifloxacin sodium chloride injection in the treatment of respiratory and urinary tract bacterial infections caused by routine pathogens. Methods: Gatifloxacin injection as a control drug, a randomized double-blind controlled experimental study. Results: The total clinical effective rate of Gatifloxacin sodium chloride injection group in treating respiratory tract and urinary tract infection was 92.5%, which was significantly different from that in control group (87.5%). The incidence of adverse reactions was 7.5%, with no significant difference compared with the control group (12.5%). Conclusions: Gatifloxacin mesylate sodium chloride injection is effective in treating respiratory and urinary tract infections caused by common pathogenic bacteria, and the incidence of adverse drug reactions is low.